A Moloney murine leukemia virus-based retrovirus with 4070A long terminal repeat sequences induces a high incidence of myeloid as well as lymphoid neoplasms - PubMed (original) (raw)
A Moloney murine leukemia virus-based retrovirus with 4070A long terminal repeat sequences induces a high incidence of myeloid as well as lymphoid neoplasms
Linda Wolff et al. J Virol. 2003 Apr.
Abstract
Retroviruses can be used to accelerate hematopoietic cancers predisposed to neoplastic disease by prior genetic manipulations such as in transgenic or knockout mice. The virus imparts a second neoplastic "hit," providing evidence that the initial hit is transforming. In the present study, a unique retrovirus was developed that can induce a high incidence of myeloid disease and has a broad host range. This agent is a Moloney murine leukemia virus (Mo-MuLV)-based virus that has most of the U3 region of the long terminal repeat (LTR) replaced with that of retrovirus 4070A. Like Mo-MuLV, this virus, called MOL4070LTR, is NB-tropic and not restricted by Fv1 allelles. MOL4070LTR causes myeloid leukemias in ca. 50% of mice, a finding in contrast to Mo-MuLV, which induces almost exclusively lymphoid disease. The data suggest that the LTR of the 4070A virus expands the tissue tropism of the disease to the myeloid lineage. Interesting, MCF recombinant envelope was expressed in the lymphoid but not the myeloid neoplasms of BALB/c mice. This retrovirus has the potential for accelerating myeloid disease in genetically engineered mice.
Figures
FIG.1.
Cytospin of spleen cells from mouse 58B-2, which was diagnosed with myelomonocytic leukemia. Magnification, ×240.
FIG. 2.
Immunohistochemistry of spleen and liver tissue from BALB/c mouse 58B-2 inoculated with MOL4070ALTR and diagnosed with myelomonocytic leukemia. Staining was performed with antibody to myeloperoxidase, F4/80, and CD3 antibody. Magnification, ×60. The white arrow indicates the location of the PALS; the black arrows point to neoplastic cells.
FIG. 3.
Immunohistochemistry of spleen and liver tissue from FVB mouse 57-10 inoculated with MOL4070ALTR and diagnosed with monocytic leukemia. Staining was performed with antibody to myeloperoxidase, F4/80, and CD3 antibody. Magnification, ×60. The white arrow indicates the PALS; the black arrows point to neoplastic cells.
FIG. 4.
Immunohistochemistry of spleen and liver tissue from FVB mouse 57-11 inoculated with MOL4070ALTR and diagnosed with a lymphoblastic T-cell lymphoma. Staining was performed with antibodies to myeloperoxidase, F4/80, and CD3 antibody. Magnification, ×60. The white arrow indicates the PALS; the black arrows point to neoplastic cells.
FIG. 5.
Proviral integrations in MOL4070ALTR-induced neoplasms. Genomic DNA was isolated from the spleens, which were enlarged in each case and shown to contain hematopoietic neoplasms. The DNA (15 μg) was digested with _Eco_RI and separated on 7% agarose gels. After being blotted onto Nytran (Schleicher & Schuell), hybridization was performed with a 4070A-specific LTR probe (31). M, myeloid; L, lymphoid.
FIG. 6.
Detection of MCF viral envelope in hematopoeitic neoplasms. Western blot analyses were performed on spleen tissues with monoclonal antibody 7C10, which specifically recognizes MCF viral envelope protein (32). A total of 50 μg of protein was electrophoresed and analyzed as reported elsewhere (20). (A) Mo-MuLV-induced T-cell lymphoblastic lymphomas were used as a positive control, and a spleen from a normal BALB/c mouse was used as a negative control. Neoplasms whose designations begin with “52” are from FVB mice. Neoplasms whose designations begin with “59A” are from BALB/c mice. (B) MOL4070LTR-induced neoplasms. Neoplasms whose designations begin with “57” are from FVB mice, and those whose designations begin with “58B” are from BALB/c mice. M, myeloid; L, lymphoid. (C) Table summarizing the results from panel B.
Similar articles
- Analysis of the disease potential of a recombinant retrovirus containing Friend murine leukemia virus sequences and a unique long terminal repeat from feline leukemia virus.
Nishigaki K, Hanson C, Thompson D, Yugawa T, Hisasue M, Tsujimoto H, Ruscetti S. Nishigaki K, et al. J Virol. 2002 Feb;76(3):1527-32. doi: 10.1128/jvi.76.3.1527-1532.2002. J Virol. 2002. PMID: 11773427 Free PMC article. - Introduction of a cis-acting mutation in the capsid-coding gene of moloney murine leukemia virus extends its leukemogenic properties.
Audit M, Déjardin J, Hohl B, Sidobre C, Hope TJ, Mougel M, Sitbon M. Audit M, et al. J Virol. 1999 Dec;73(12):10472-9. doi: 10.1128/JVI.73.12.10472-10479.1999. J Virol. 1999. PMID: 10559365 Free PMC article. - Leukemogenesis by Moloney murine leukemia virus: a multistep process.
Fan H. Fan H. Trends Microbiol. 1997 Feb;5(2):74-82. doi: 10.1016/S0966-842X(96)10076-7. Trends Microbiol. 1997. PMID: 9108934 Review. - The pathophysiology of murine retrovirus-induced leukemias.
Schiff RD, Oliff A. Schiff RD, et al. Crit Rev Oncol Hematol. 1986;5(3):257-323. doi: 10.1016/s1040-8428(86)80041-5. Crit Rev Oncol Hematol. 1986. PMID: 3527464 Review.
Cited by
- Multi-Walled Carbon Nanotubes Accelerate Leukaemia Development in a Mouse Model.
Wang Q, Han J, Wei M, Miao H, Zhang M, Wu B, Chen Y, Zheng Y, Xu H, Gale RP, Yin B. Wang Q, et al. Toxics. 2024 Sep 2;12(9):646. doi: 10.3390/toxics12090646. Toxics. 2024. PMID: 39330574 Free PMC article. - 5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignancies.
Wong JC, Weinfurtner KM, Westover T, Kim J, Lebish EJ, Del Pilar Alzamora M, Huang BJ, Walsh M, Abdelhamed S, Ma J, Klco JM, Shannon K. Wong JC, et al. Leukemia. 2024 May;38(5):1182-1186. doi: 10.1038/s41375-024-02205-x. Epub 2024 Mar 5. Leukemia. 2024. PMID: 38443608 Free PMC article. - Opposing effects of KDM6A and JDP2 on glucocorticoid sensitivity in T-ALL.
Levinson AL, Tjoa K, Huang B, Meyer LK, Kim MO, Brady SW, Zhang J, Shannon K, Wandler AM. Levinson AL, et al. Blood Adv. 2023 Jul 25;7(14):3479-3484. doi: 10.1182/bloodadvances.2021006881. Blood Adv. 2023. PMID: 36897249 Free PMC article. - WDR26 and MTF2 are therapeutic targets in multiple myeloma.
Sun F, Cheng Y, Riordan JD, Dupuy A, Dubois W, Pisano M, Dong J, Mock B, Zhan F, Hari P, Janz S. Sun F, et al. J Hematol Oncol. 2021 Dec 7;14(1):203. doi: 10.1186/s13045-021-01217-9. J Hematol Oncol. 2021. PMID: 34876184 Free PMC article. - Kdm6a deficiency restricted to mouse hematopoietic cells causes an age- and sex-dependent myelodysplastic syndrome-like phenotype.
Tian L, Chavez M, Chang GS, Helton NM, Katerndahl CDS, Miller CA, Wartman LD. Tian L, et al. PLoS One. 2021 Nov 15;16(11):e0255706. doi: 10.1371/journal.pone.0255706. eCollection 2021. PLoS One. 2021. PMID: 34780480 Free PMC article.
References
- Athias, G. B., C. R. Starkey, and L. S. Levy. 1994. Retroviral determinants of leukemogenesis. Crit. Rev. Oncog. 5:169-199. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources